Clinical Trials Browser

Phase 2 × Glioblastoma × Ramucirumab × Clear all

NCT00895180 2017-12-27

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 2 Completed

80 enrolled 15 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma